Male and Female patients ≥ 40 years old at the time of BDP/FF/GB initiation
Patients with documented diagnosis of severe or very severe COPD prior to BDP/FF/GB initiation
Patients with CAT total score ≥ 10 at baseline (at the time of BDP/FF/GB initiation or within the 12 months before treatment initiation\*) \*If no CAT total score is available on BDP/FF/GB initiation date)
Patients with at least ≥ 1 COPD exacerbation within the previous 12 months before enrollment.
Patients who started treatment with BDP/FF/GB within 3-months before signing the Informed Consent Form (ICF), or on the date of the ICF signature according to Trimbow® Summary of Product Characteristics (SmPC)
Patients who are willing and able to give their written consent to participate in the study
You may not be if
\- Patient known to be participating in any interventional study during the study period and in the 3 months prior to BDP/FF/GB initiation.
Clareo Health | Real-World Effectiveness of a Triple Combination BDP/FF/GB Extrafine in a Single Pressurised Metered Dose Inhaler in Brazilian COPD Patients
